Skip to Content
Merck
CN
  • Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: in vitro and in vivo investigations.

Sterically stabilized polymeric nanoparticles with a combinatorial approach for multi drug resistant cancer: in vitro and in vivo investigations.

International journal of pharmaceutics (2014-12-03)
Sobiya Zafar, Lalit Mohan Negi, Anita Kamra Verma, Vijay Kumar, Aakriti Tyagi, Pratibha Singh, Zeenat Iqbal, Sushama Talegaonkar
ABSTRACT

The present work describes the preparation of sterically stabilize polymeric nanoparticles of mitoxantrone dihydrochloride (MTO) along with an efflux transporter (Pgp/BCRP) inhibitor that enhance the circulation time of nanoparticles and simultaneously surmount the problem of multidrug resistance (MDR). Mitoxantrone dihydrochloride being hydrophilic in nature had very low entrapment efficiency (%E.E.), thus in order to further enhance the lipophilicity and the %E.E., it was complexed with sodium deoxycholate (SDC) and this MTO-SDC-complex was used to formulate nanoparticles with/without Pgp/BCRP inhibitor by nanoprecipitation technique and was characterized for various in vitro and in vivo attributes. In vitro cell line studies were conducted on MCF7, A2780(p) and A2780(adr) cells. Furthermore, the targeting potential of hyaluronic acid (HA) coated nanoparticles for CD44 receptors was investigated using the MCF7 cell line. A reduction in the IC50 value observed with the inhibitor loaded nanoparticles in different cell lines indicated the BCRP/Pgp inhibiting ability of the formulated nanoparticles. The reduced macrophage uptake and the increased residence time in blood demonstrated the long circulating behaviour of the nanoparticles. The enhanced cellular uptake of HA coated nanoparticles in MCF7 cells revealed their targeting potential. The HA coated nanoparticles along with efflux transporter inhibitor exhibits a great potential for targeted chemotherapy in CD44 overexpressing MDR breast cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Trioctylamine, 98%
Sigma-Aldrich
Quercetin, ≥95% (HPLC), solid
USP
Cetrimonium bromide, United States Pharmacopeia (USP) Reference Standard
Supelco
Quercetin, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Quercetin, United States Pharmacopeia (USP) Reference Standard
Mitoxantrone hydrochloride, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Hesperetin, ≥95%
Sigma-Aldrich
Coumarin 6, ≥99%
SAFC
Sodium deoxycholate
Supelco
Hesperetin, analytical standard
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, Molecular Biology, ≥99%
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, BioXtra, ≥99%
Sigma-Aldrich
Sodium deoxycholate, ≥97% (titration)
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, ≥98%
Sigma-Aldrich
Coumarin 6, 98%
Sigma-Aldrich
Sodium deoxycholate, BioXtra, ≥98.0% (dry matter, NT)
Supelco
Hexadecyltrimethylammonium bromide, suitable for ion pair chromatography, LiChropur
Sigma-Aldrich
Sodium deoxycholate, Vetec, reagent grade, ≥97%
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, Vetec, reagent grade, 96%
Sigma-Aldrich
Mitoxantrone dihydrochloride, ≥97% (HPLC)
Sigma-Aldrich
Methyltrioxorhenium(VII), Re 71.0-76.0 %
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, ≥96.0% (AT)
Sigma-Aldrich
Hexadecyltrimethylammonium bromide, BioUltra, Molecular Biology, ≥99.0% (AT)
Supelco
Hexadecyltrimethylammonium bromide, analytical standard